HTFL: Rapid Plaque Analysis growth and new trials target a doubling of addressable market by 2029
AI-driven coronary artery disease diagnostics are seeing rapid Plaque Analysis adoption, strong revenue growth, and expanding clinical evidence. New RCTs target a $6 billion asymptomatic market, aiming to double TAM by 2029. Q2 revenue grew 48% year-over-year, with profitability expected by mid-202…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.